Getting In Cheap On Bio-Techne Corporation (NASDAQ:TECH) Is Unlikely
Getting In Cheap On Bio-Techne Corporation (NASDAQ:TECH) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may consider Bio-Techne Corporation (NASDAQ:TECH) as a stock to avoid entirely with its 43.6x P/E ratio. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.
Recent times haven't been advantageous for Bio-Techne as its earnings have been falling quicker than most other companies. One possibility is that the P/E is high because investors think the company will turn things around completely and accelerate past most others in the market. If not, then existing shareholders may be very nervous about the viability of the share price.
Keen to find out how analysts think Bio-Techne's future stacks up against the industry? In that case, our free report is a great place to start.Is There Enough Growth For Bio-Techne?
There's an inherent assumption that a company should far outperform the market for P/E ratios like Bio-Techne's to be considered reasonable.
Retrospectively, the last year delivered a frustrating 15% decrease to the company's bottom line. Regardless, EPS has managed to lift by a handy 25% in aggregate from three years ago, thanks to the earlier period of growth. So we can start by confirming that the company has generally done a good job of growing earnings over that time, even though it had some hiccups along the way.
Looking ahead now, EPS is anticipated to climb by 5.7% per annum during the coming three years according to the analysts following the company. That's shaping up to be materially lower than the 10% per year growth forecast for the broader market.
With this information, we find it concerning that Bio-Techne is trading at a P/E higher than the market. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. Only the boldest would assume these prices are sustainable as this level of earnings growth is likely to weigh heavily on the share price eventually.
What We Can Learn From Bio-Techne's P/E?
Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
We've established that Bio-Techne currently trades on a much higher than expected P/E since its forecast growth is lower than the wider market. Right now we are increasingly uncomfortable with the high P/E as the predicted future earnings aren't likely to support such positive sentiment for long. This places shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.
You always need to take note of risks, for example - Bio-Techne has 1 warning sign we think you should be aware of.
You might be able to find a better investment than Bio-Techne. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
當將近一半的美國公司的市盈率(或 “市盈率”)低於16倍時,你可以考慮將生物技術公司(納斯達克股票代碼:TECH)作爲股票,以其43.6倍的市盈率完全避免。但是,僅按面值計算市盈率是不明智的,因爲可以解釋爲什麼市盈率如此之高。
最近對Bio-Techne來說並不是有利的,因爲其收益的下降速度比大多數其他公司快。一種可能性是市盈率居高不下,因爲投資者認爲該公司將徹底扭轉局面,加速超越市場上的大多數其他公司。如果不是,那麼現有股東可能會對股價的可行性感到非常擔憂。
想了解分析師如何看待Bio-Techne的未來與該行業的對立嗎?在這種情況下,我們的免費報告是一個很好的起點。生物技術有足夠的增長嗎?
人們固有的假設是,如果像Bio-Techne這樣的市盈率被認爲是合理的,公司的表現應該遠遠超過市場。
回顧過去,去年該公司的利潤下降了15%,令人沮喪。無論如何,由於較早的增長,每股收益總共比三年前增長了25%。因此,我們可以首先確認該公司在此期間在增加收益方面總體上做得很好,儘管在此過程中遇到了一些小問題。
根據關注該公司的分析師的說法,展望未來,預計未來三年每股收益將每年增長5.7%。這將大大低於整個市場每年10%的增長預期。
有了這些信息,我們發現Bio-Techne的交易市盈率高於市場。看來大多數投資者都希望公司的業務前景出現轉機,但分析師對這種情況會發生的信心不大。只有最大膽的人才會假設這些價格是可持續的,因爲這種收益增長水平最終可能會嚴重壓制股價。
我們可以從Bio-Techne的市盈率中學到什麼?
通常,在做出投資決策時,我們會謹慎行事,不要過多地閱讀市盈率,儘管這可以充分揭示其他市場參與者對公司的看法。
我們已經確定,Bio-Techne目前的市盈率遠高於預期,因爲其預測的增長低於整個市場。目前,我們對高市盈率越來越不滿意,因爲預期的未來收益不太可能長期支撐這種積極情緒。這使股東的投資面臨重大風險,潛在投資者面臨支付過高溢價的危險。
你需要時刻注意風險,例如——Bio-Techne有1個我們認爲你應該注意的警告信號。
你也許能找到比Bio-Techne更好的投資。如果你想選擇可能的候選人,可以免費查看這份有趣的公司名單,這些公司的市盈率很低(但已經證明可以增加收益)。
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧